

PRIOR AUTHORIZATION CRITERIA

**BRAND NAME
(generic)**

**ALBENZA
(albendazole)**

**BILTRICIDE
(praziquantel)**

**EGATEN
(triclabendazole)**

**EMVERM
(mebendazole)**

Status: CVS Caremark Criteria

Type: Post Limit Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Albenza

Neurocysticercosis

Albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, *Taenia solium*.

Hydatid Disease

Albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, *Echinococcus granulosus*.

Biltricide

Biltricide is indicated in patients aged 1 year and older for the treatment of the following infections:

Schistosomiasis due to all species of schistosoma (for example, *Schistosoma mekongi*, *Schistosoma japonicum*, *Schistosoma mansoni* and *Schistosoma hematobium*), and Clonorchiasis and Opisthorchiasis due to the liver flukes, *Clonorchis sinensis*/*Opisthorchis viverrini* (approval of this indication was based on studies in which the two species were not differentiated)

Compendial Uses

Treatment of intestinal infections caused by *Taenia solium*, *Taenia saginata*, *Diphyllobothrium latum* and *Hymenolepis nana*.

Egaten

Egaten is indicated for the treatment of fascioliasis in patients 6 years of age or older

Emverm

Emverm is indicated for the treatment of patients two years of age and older with gastrointestinal infections caused by *Ancylostoma duodenale* (hookworm), *Ascaris lumbricoides* (roundworm), *Enterobius vermicularis* (pinworm), *Necator americanus* (hookworm), and *Trichuris trichiura* (whipworm).

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The infection has been confirmed by a diagnostic or laboratory test (e.g. imaging scans, blood, stool, or urine test)

AND

- The request is for mebendazole (Emverm) in a patient 2 years of age or older for a second course of therapy (first course of therapy administered within the past year) at a dose up to 2 tablets per day for two 3 day treatments for any of the following: A) *Ancylostoma duodenale* (hookworm), B) *Ascaris lumbricoides* (roundworm), C) *Enterobius vermicularis* (pinworm), D) *Necator americanus* (hookworm), E) *Trichuris trichiura* (whipworm).

OR

- The request is for albendazole (Albenza) for the treatment of Hydatid Disease for a second course of therapy (first course of therapy administered within the past year) at a dose up to 4 tablets per day for three 28-day cycles with 14-day free intervals

OR

- The request is for praziquantel (Biltricide) in a patient 1 year of age or older for the treatment of schistosomiasis, clonorchiasis, or opisthorchiasis for any of the following: A) a quantity up to 36 tablets, B) a second day or course of therapy (first course of therapy administered within the past year)

OR

- The request is for triclabendazole (Egaten) in a patient 6 years of age or older for the treatment of fascioliasis for any of the following: A) a quantity up to 32 tablets, B) a second day or course of therapy (first course of therapy administered within the past year)

Quantity Limits apply.

Emverm (mebendazole): 12 tablets per 365 days

Albenza (albendazole): 336 tablets per 365 days

Biltricide (praziquantel): 72 tablets per 365 days

Egaten (triclabendazole): 32 tablets per 365 days

REFERENCES

1. Albenza [package insert]. Horsham, PA: Amedra Pharmaceuticals LLC; June 2019.
2. Biltricide [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; January 2019.
3. Egaten [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; September 2019
4. Emverm [package insert]. Horsham, PA: Amedra Pharmaceuticals LLC; January 2019.
5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed February 1, 2021, Year.
6. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed February 1, 2021.
7. Parasites - Schistosomiasis. Available at: https://www.cdc.gov/parasites/schistosomiasis/health_professionals/index.html#tx. Accessed February 2021.
8. Parasites – Clonorchis. Available at: https://www.cdc.gov/parasites/clonorchis/health_professionals/index.html. Accessed February 2021.
9. Parasites - Opisthorchis Infection. Available at: https://www.cdc.gov/parasites/opisthorchis/health_professionals/index.html. Accessed February 2021.
10. Parasites - Echinococcosis. Available at: <https://www.cdc.gov/parasites/echinococcosis/>. Accessed February 2021.
11. Parasites – Cysticercosis. Available at: <https://www.cdc.gov/parasites/cysticercosis/>. Accessed February 2021.
12. Parasites - Fasciola. Available at: https://www.cdc.gov/parasites/fasciola/health_professionals/index.html#tx. Accessed February 2021.
13. Parasites – Taeniasis. Available at: https://www.cdc.gov/parasites/taeniasis/health_professionals/index.html#tx/. Accessed February 2021.
14. Parasites – Diphyllbothrium. Available at: https://www.cdc.gov/parasites/diphyllbothrium/health_professionals/index.html/. Accessed February 2021.

15. Parasites – Hymenolepiasis. Available at:
https://www.cdc.gov/parasites/hymenolepis/health_professionals/index.html. Accessed February 2021.
16. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. Vital Health Stat 3(46). 2021. Available at:
https://www.cdc.gov/nchs/data/series/sr_03/sr03_039.pdf. Accessed February 2021.